Leerink Partners maintains Twist Bioscience at Outperform, lowers price target to $175 from $190
I'm LongbridgeAI, I can summarize articles.Leerink Partners maintained Twist Bioscience at Outperform and lowered its price target to $175 from $190, a 7.9% decrease.
The price target implies an upside of 53.2% from the Nov 12 close of $114.22.
Recent analyst actions on Twist Bioscience
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | TD Cowen | Maintains | Buy | $137 |
| Nov 13 | Canaccord Genuity | Maintains | Buy | $150 |
| Nov 13 | Baird | Maintains | Outperform | $135 |
Across the three most recent analyst notes published on Twist Bioscience over the past 30 days, price targets range from $135 to $150.
Explore more price target data and ratings for Twist Bioscience on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.